Product Description
Reference Standards &Impurity
AI Product Description
*The following content is generated by AI and is for reference only.
Frovatriptan is a selective serotonin 5-HT1B/1D receptor agonist belonging to the triptan class of medications, primarily utilized for the acute treatment of migraine attacks with or without aura. Chemically known as 3-[2-(dimethylamino)ethyl]-N,N-dimethyl-6-methoxyindole-2-propanamide, its molecular formula is C18H27N3O2. The compound carries the CAS registry number 139042-98-9 and features a unique chemical structure that enhances its binding affinity for specific serotonin receptors while minimizing interaction with other vascular receptors, thereby reducing the risk of vasoconstriction-related side effects compared to earlier generation agents.
Developed to address the limitations of existing triptans, such as short half-lives leading to high recurrence rates of migraines, Frovatriptan boasts an exceptionally long elimination half-life of approximately 26 hours. This pharmacokinetic profile allows for sustained relief from migraine symptoms and significantly lowers the probability of headache recurrence within 24 to 48 hours post-administration. Clinically, it is indicated for patients who experience frequent migraine recurrences despite using shorter-acting therapies. The drug is typically administered orally in tablet form, with dosages ranging from 2.5 mg to 5 mg depending on individual patient response and physician guidance.
While generally well-tolerated, common adverse effects may include dizziness, somnolence, fatigue, and sensations of tingling or warmth. As with all triptans, Frovatriptan is contraindicated in patients with uncontrolled hypertension, ischemic heart disease, history of stroke, or hemiplegic and basilar migraines due to potential cardiovascular risks. It should not be used concurrently with monoamine oxidase inhibitors or within two weeks of their discontinuation. Furthermore, medication overuse headache can occur if the drug is taken more than ten days per month. Despite these precautions, Frovatriptan remains a valuable therapeutic option in neurology, offering extended protection against migraine recurrence and improving quality of life for sufferers requiring longer-lasting acute intervention. Its distinct pharmacological properties make it a preferred choice for specific clinical scenarios where prolonged symptom control is essential.